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The synthesis of new pyrazine substituted 1,3,4-thiadiazole derivatives was carried out in good yield by the reaction of pyrazine
substituted 1,3,4-thiadiazoles with various sulfonyl chlorides. A chemical structure of all the new compounds was confirmed by 1H
NMR and mass spectral data. The new compounds were screened for their anticonvulsant activity against maximal electroshock
(MES) seizuremethod. Rotarodmethodwas employed to determine the neurotoxicity. Few compounds showed significant changes
in anticonvulsant activity. The same compounds showed no neurotoxicity at the maximum dose administered (100mg/kg).
1. Introduction
Epilepsy has been recognized as a neurological disorder,
affecting a large section of people across the world. The word
epilepsy usually describes a group of common chronic neu-
rological disorders characterized by recurrent unprovoked
seizures due to excessive neuronal firing or synchronous
neuronal activity in the brain [1, 2]. Seizures may vary from
the briefest lapses of attention or muscle jerks to severe
and prolonged convulsions [3]. The maximal electroshock
(MES) test is a predictor of compounds that are active against
seizures [4]. The anticonvulsant drug design is based on the
presumption that at least one phenyl or similar aromatic
group in close proximity to two electron donor atoms in the
compound is required for the activity in MES [5, 6]. Newer
drugs such as flupirtine [7], topiramate [8], zonisamide [9],
and vigabatrin [10] have emerged as promising anticonvul-
sants.
Pyrazines and its derivatives play an important role in the
drug discovery realm. In particular the structural analogue of
purines derivatives presents various pharmacological activi-
ties such as antibacterial [11], anti-inflammatory [12], antide-
pressant [13], and antiproliferative activities [14].Thiadiazoles
exhibit a broad spectrum of biological effectiveness such as
antiparkinsonism [11], antihistaminic [15], and antiasthmatic
[16]. Thiazolidin-4-one derivatives are also known to exhibit
diverse bioactivities such as anticonvulsant [17], antidiarrheal
[18], antihistaminic [19], antidiabetic [20], cardioprotective
[21], and anticancer [22]. Similarly, 2,5-disubstituted 1,3,4-
thiadiazoles also display wide spectrum of activities such
as antibacterial [23] and anticonvulsant [24]. In the present
study, a series of new pyrazine substituted 1,3,4-thiadiazole
derivatives 7(a–o) have been synthesized and their anticon-
vulsant effects are determined throughmaximal electroshock
(MES) seizure test.
2. Materials and Methods
2.1. Chemistry. Melting range was determined by Veego
Melting Point VMP III apparatus. Elemental analyses were
recorded on VarioMICRO superuser V1.3.2 Elementar. 1H
NMR spectra were recorded on Bruker DRX-500 spectrom-
eter at 400MHz using DMSO-d
6
as solvent and TMS as
an internal standard. Mass spectral data were obtained by
LC/MSD Trap XCT. Silica gel column chromatography was
performed using Merck 7734 silica gel (60–120 mesh) and
Merck-made TLC plates.
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2.1.1. Preparation of 1,3,4-Thiadiazole-2-ylamine (2). Thi-
osemicarbazide (1, 50.0 g, 0.5486mol) was taken in 100mL
formic acid and the reaction was stirred at room temperature
for 1 hr. The reaction was cooled and 100mL conc. hydro-
chloric acid was added. Reaction completion was monitored
by TLC. The reaction was cooled to 0∘C and basified with
ammonium hydroxide solution. The solid formed was fil-
tered, washed with water, and dried to yield the above
compound as off white solid (Yield: 45.50 g, 82%). 1H-
NMR (400MHz, DMSO-d
6
): 𝛿 4.21 (s, br, 2H), 9.31 (s, 1H).
MS (ESI)m/z: 102.14.
2.1.2. Preparation of 5-Bromo-1,3,4-thiadiazol-2-amine (3).
To a stirred solution of 2 (40.0 g), sodium acetate (64.89 g) in
200mL acetic acid (4.0 vol) at 10∘C, bromine was added drop
wise (37.92 g). The reaction was stirred at room temperature
for 3 hours. The reaction was concentrated and basified with
saturated sodium bicarbonate solution. The compound was
extracted with ethyl acetate and the ethyl acetate layer was
washed with water followed by brine, dried over sodium
sulphate. The crude product was crystallized using ethyl
acetate to yield the above compound as off white solid (Yield:
53.4 g, 75%). 1H-NMR (400MHz, DMSO-d
6
): 𝛿 4.21 (s, br,
2H). MS (ESI)m/z: 181.10.
2.1.3. Preparation of tert-Butyl 4-(5-amino-1,3,4-thiadiazole-
2-yl)piperazine-1-carboxylate (4). To a stirred solution of 3
(25.0 g, 0.1388mol), potassium carbonate (57.57 g, 0.4165
mol) in dimethyl formamide (250mL) and mono boc piper-
azine (31.03 g, 0.1666mol) were added and stirred the
reaction for 10 hr at room temperature. The reaction was
quenched into ice water (2.0 L) and stirred at room temper-
ature for 1 hr. Solid formed was filtered and dried to yield
the above compound as off white solid (Yield: 33.6 g, 85%).
1H-NMR (400MHz, DMSO-d
6
): 𝛿 1.41 (s, 9H), 3.10 (t, J =
4.80Hz, 4H), 3.77 (t, J = 5.36Hz, 4H), 4.21 (s, 2H). MS (ESI)
m/z: 286.03.
2.1.4. Preparation of tert-Butyl-4-(5-(pyrazine-2-carbox-
amido)-1,3,4-thiadiazol-2-yl)piperazine-1-carboxylate (5). To
a stirred solution of 4 (25.0 g, 0.0876mol), in dichloro-
methane (250mL), triethyl amine (26.59 g, 0.2628mol),
pyrazine-2-carboxylic acid (13.04 g, 0.1051mol) and TBTU
(33.75 g, 0.1051mol) were added. The reaction was stirred
overnight at room temperature and the reaction completion
was monitored by TLC. The reaction was washed with
saturated bicarbonate solution followed by 1.0N HCl, water,
and brine. The organic layer was dried over sodium sulphate,
concentrated, and crystallized using dichloromethane to
yield the above compound as off white solid (Yield: 28.80 g,
84%). 1H-NMR (400MHz, DMSO-d
6
): 𝛿 1.41 (s, 9H), 3.23
(t, J = 3.76Hz, 4H), 3.75 (t, J = 4.40Hz, 4H), 8.83 (d, J =
2.00Hz, 1H), 8.94 (d, J = 2.00Hz, 1H), 9.25 (s, 1H), 9.72 (s,
2H).
2.1.5. Preparation of N-(5-(Piperazine-1-yl)-1,3,4-thiadiazole-
2-yl)pyrazine-2-carboxamide hydrochloride (6). To a stirred
solution of 5 (20 g, 0.0687mol) in 1,4 dioxane at 0–5∘C,
4N HCl in dioxane (80.0mL) was added. The reaction was
stirred at room temperature for 10 hr. The solid was filtered,
washed with diethyl ether, and packed in air tight container
to yield the above compound as pale yellow hygroscopic solid
(16.73 g, 90%). 1H-NMR (400MHz, DMSO-d
6
): 𝛿 3.22 (t, J =
3.75Hz, 4H), 3.73 (t, J = 4.30Hz, 4H), 8.83 (d, J = 2.00Hz,
1H), 8.94 (d, J = 2.00Hz, 1H), 9.27 (s, 1H), 9.72 (s, 2H). MS
(ESI)m/z: 292.05.
2.1.6. General Procedure for the Synthesis of Pyrazine Substi-
tuted 1,3,4-Thiadiazole Derivatives 7(a–o). To a mixture of 6
(1.0 eq) and triethyl amine (4.5 eq) in dichloromethane (10
volume), substituted sulphonyl chloride (2.4 eq) was added at
5–10∘C and stirred overnight at room temperature. Reaction
completion was confirmed through TLC. The reaction was
poured into separating funnel, washed with water followed
by brine solution, and dried over anhydrous sodium sulphate.
Crude product was purified by crystallization using ethyl
acetate to yield the thiadiazole substituted sulfonamide as off
white to pale yellow solids.
(1) N-(5-(4-((1,l’-Biphenyl)sulfonyl)piperazine-1-yl)-1,3,4-thia-
diazole-2-yl)pyrazine-2-carboxamide (7a). Yield: 70% (White
solid); 1H-NMR (400MHz, DMSO-d
6
): 𝛿 3.18 (t, J = 4.10Hz,
4H), 3.67 (t, J = 5.02Hz, 4H), 7.40–7.52 (m, 3H), 7.64–7.87
(m, 6H), 8.81 (d, J = 2.35Hz, 1H), 8.90 (d, J = 2.45Hz, 1H),











: C, 54.42; H, 4.17; N, 19.32; Found: C, 54.13; H,
4.32; N, 19.52%.
(2) N-(5-(4-((2,4-Dimethylphenyl)sulfonyl)piperazine-1-yl)-1,
3,4-thiadiazole-2-yl)pyrazine-2-carboxamide (7b). Yield: 72%
(Off white solid); 1H-NMR (400MHz, DMSO-d
6
): 𝛿 2.34 (s,
3H), 2.37 (s, 3H), 3.21 (t, J = 4.01Hz, 4H), 3.68 (t, J = 4.90Hz,
4H), 7.22 (s, 1H), 7.42 (d, J = 6.35Hz, 2H), 8.70 (d, J = 2.25Hz,
1H), 8.81 (d, J = 2.46Hz, 1H), 9.16 (s, 1H), 12.3 (s, 1H).MS (ESI)












: C, 49.66; H,
4.61; N, 21.34; Found: C, 49.75; H, 4.68; N, 21.46%.
(3) N-(5-(4-(Methylsulfonyl)piperazine-1-yl)-1,3,4-thiadiazole
-2-yl)pyrazine-2-carboxamide (7c). Yield: 72% (White solid);
1H-NMR (400MHz, DMSO-d
6
): 𝛿 2.35 (s, 3H), 3.23 (t, J =
3.86Hz, 4H), 3.72 (t, J = 4.31Hz, 4H), 8.83 (d, J = 2.00Hz,
1H), 8.94 (d, J = 2.00Hz, 1H), 9.27 (s, 1H), 12.1 (s, br, 1). MS











H, 4.09; N, 26.54; Found: C, 38.97; H, 3.96; N, 26.74%.
(4) N-(5-(4-((2,5-Dichlorothiophen-3-yl)sulfonyl)piperazine-
1-yl)-1,3,4-thiadiazole-2-yl)pyrazine-2-carboxamide (7d).
Yield: 74% (Off white solid); 1H-NMR (400MHz, DMSO-
d
6
): 𝛿 3.31 (t, J = 4.08Hz, 4H), 3.61 (t, J = 3.84Hz, 4H), 7.43
(s, 1H), 8.83 (d, J = 2.20Hz, 1H), 8.95 (d, J = 2.24Hz, 1H),













: C, 35.58; H, 2.59; N, 19.36; Found: C,
35.35; H, 2.75; N, 19.54%.
(5) N-(Naphthalene-2-ylsulfonyl)-N-(5-(4-(naphthalene-2-yl-
sulfonyl)piperazine-1-yl)-1,3,4-thiadiazole-2-yl)pyrazine-2-
carboxamide (7e). Yield: 75% (Off white solid); 1H-NMR
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(400MHz, DMSO-d
6
): 𝛿 3.14 (t, J = 4.96Hz, 4H), 3.57 (t, J =
5.36Hz, 4H), 7.50–7.54 (m, 2H), 7.67–7.79 (m, 5H), 7.85–7.87
(m, 1H), 7.88–7.91 (m, 1H), 8.09–8.24 (m, 4H), 8.48 (s, 1H),
8.80 (d, J = 2.32Hz, 1H), 8.92 (d, J = 2.44Hz, 1H), 9.23 (s, 1H).











55.43; H, 3.75; N, 14.60; Found: C, 55.54; H, 3.65; N, 14.42%.
(6) N-(5-(4-((3,5-Dimethylisoxazol-4-yl)sulfonyl)piperazine-
1-yl)1,3,4-thiadiazole-2-yl) pyrazine-2-carboxamide (7f ).
Yield: 73% (Off white solid); 1H-NMR (400MHz, DMSO-
d
6
): 𝛿 2.34 (s, 3H), 2.62 (s, 3H), 3.22 (t, J = 4.92Hz, 4H), 3.58
(t, J = 5.28Hz, 4H), 8.82 (d, J = 2.36Hz, 1H), 8.93 (d, J =
2.44Hz, 1H), 9.26 (s, 1H), 12.30 (s, 1H). MS (ESI)m/z: 451.00.










: C, 42.66; H, 4.03; N, 24.87;
Found: C, 42.78; H, 4.30; N, 24.75%.
(7) N-(5-(4-((3,5-Bis(trifluoromethyl)phenyl)sulfonyl)piper-
azine-1-yl)-1,3,4-thiazol-2-yl) pyrazine-2-carboxamide (7g).
Yield: 72% (Off white solid); 1H-NMR (400MHz, DMSO-
d
6
): 𝛿 3.31 (t, J = 4.08Hz, 4H), 3.88 (t, J = 4.96Hz, 4H), 8.15
(s, 1H), 8.23 (s, br, 2H), 8.71 (d, J = 2.16Hz, 1H), 8.74 (s, 1H),
8.91 (d, J = 2.28Hz, 1H), 9.47 (s, 1H). MS (ESI) m/z: 566.40.












: C, 40.21; H, 2.66; N, 17.28;
Found: C, 40.28; H, 2.54; N, 17.43%.
(8) N-(5-(4-Tosylpiperazine-1-yl)-1,3,4-thiadiazole-2-yl)pyr-
azine-2-carboxamide (7h). Yield: 71% (Off white solid);
1H-NMR (400MHz, DMSO-d
6
): 𝛿 2.24 (s, 3H), 3.25 (t, J =
4.82Hz, 4H), 3.78 (t, J = 5.08Hz, 4H), 7.75 (d, J = 8.58Hz,
2H), 8.12 (d, J = 8.13Hz, 2H), 8.82 (d, J = 2.26Hz, 1H), 8.93
(d, J = 2.34Hz, 1H), 9.23 (s, 1H), 12.27 (s, 1H). MS (ESI) m/z:










: C, 48.53; H, 4.30; N,
22.01; Found: C, 48.67; H, 4.42; N, 22.31%.
(9) N-(5-(4-((4-(tert-Butyl)phenyl)sulfonyl)piperazine-1-yl)-
1,3,4-thiadiazole-2-yl)pyrazine-2-carboxamide (7i). Yield:
73% (Off white solid); 1H-NMR (400MHz, DMSO-d
6
): 𝛿
1.14 (s, 9H), 3.41 (t, J = 4.72Hz, 4H), 3.93 (t, J = 5.28Hz, 4H),
7.72 (d, J = 7.68Hz, 2H), 7.99 (d, J = 7.83Hz, 2H), 8.80 (d, J =
2.27Hz, 1H), 8.91 (d, J = 2.44Hz, 1H), 9.21 (s, 1H), 12.23 (s,











C, 51.73; H, 5.17; N, 20.11; Found: C, 51.53; H, 5.32; N, 20.32%.
(10) N-(5-(4-((3-(Trifluoromethyl)phenyl)sulfonyl)piperazine-
1-yl)-1,3,4-thiadiazole-2-yl)pyrazine-2-carboxamide (7j).
Yield: 73% (Off white solid); 1H-NMR (400MHz, DMSO-
d
6
): 𝛿 3.15 (t, J = 4.40Hz, 4H), 3.60 (t, J = 5.20Hz, 4H),
7.90–7.94 (m, 1H), 8.00 (s, 1H), 8.09–8.14 (m, 2H), 8.78
(d, J = 2.26Hz, 1H), 8.85 (d, J = 2.44Hz, 1H), 9.23 (s,













: C, 43.28; H, 3.23; N, 19.63; Found: C,
43.43; H, 3.43; N, 19.73%.
(11) N-(5-(4-((4-Iodophenyl)sulfonyl)piperazine-1-yl)-1,3,4-
thiadiazole-2-yl)pyrazine-2-carboxamide (7k). Yield: 71%
(Off white solid); 1H-NMR (400MHz, DMSO-d
6
): 𝛿 3.06 (t,
J = 3.80Hz, 4H), 3.45 (t, J = 4.10Hz, 4H), 7.68 (d, J = 7.05Hz,
2H), 7.86 (d, J = 6.75Hz, 2H), 8.78 (d, J = 2.22Hz, 1H), 8.92
(d, J = 2.34Hz, 1H), 9.24 (s, 1H), 12.28 (s, 1H). MS (ESI) m/z:










: C, 36.63; H, 2.89;
N, 17.59; Found: C, 36.53; H, 2.75; N, 17.64%.
(12) N-(5-(4-((Cyclopropane)sulfonyl)piperazine-1-yl)-1,3,4-
thiadiazole-2-yl)pyrazine-2-carboxamide (7l). Yield: 75% (Off
white solid); 1H-NMR (400MHz, DMSO-d
6
): 𝛿 0.7-0.8 (m,
4H), 1.0–1.02 (m, 1H), 3.26 (t, J = 3.70Hz, 4H), 3.72 (t, J =
4.28Hz, 4H), 8.83 (d, J = 2.20Hz, 1H), 8.94 (d, J = 2.32Hz,











: C, 42.52; H, 4.33; N, 24.79; Found:
C, 42.43; H, 4.54; N, 24.86%.
(13) N-(5-(4-((2-Nitro-4-(trifluoromethyl)phenyl)sulfonyl)pip-
erazine-1-yl)-1,3,4-thiadiazole-2-yl)pyrazine-2-carboxamide
(7m). Yield: 75% (Off white solid); 1H-NMR (400MHz,
DMSO-d
6
): 𝛿 3.31 (t, J = 4.08Hz, 4H), 3.88 (t, J = 4.96Hz,
4H), 8.25 (s, br, 2H), 8.65 (s, 1H), 8.81 (d, J = 2.40Hz, 1H),
8.93 (d, J = 2.68Hz, 1H), 9.26 (s, 1H), 12.30 (s, 1H). MS (ESI)












: C, 39.71; H,
2.78; N, 20.58; Found: C, 39.79; H, 2.65; N, 20.76%.
(14) N-(5-(4-((4-Bromophenyl)sulfonyl)piperazine-1-yl)-1,3,4-
thiadiazole-2-yl)pyrazine-2-carboxamide (7n). Yield: 72%
(Off white solid); 1H-NMR (400MHz, DMSO-d
6
): 𝛿 3.16 (t,
J = 3.90Hz, 4H), 3.55 (t, J = 4.20Hz, 4H), 7.71 (d, J = 7.25Hz,
2H), 7.83 (d, J = 7.65Hz, 2H), 8.73 (d, J = 2.29Hz, 1H), 8.90
(d, J = 2.34Hz, 1H), 9.28 (s, 1H), 12.18 (s, 1H). MS (ESI) m/z:










: C, 40.01; H, 3.16;
N, 19.21; Found: C, 39.98; H, 3.32; N, 19.32%.
(15) N-(5-(4-((4-(Trifluoromethyl)phenyl)sulfonyl)piperazine-
1-yl)-1,3,4-thiadiazole-2-yl)pyrazine-2-carboxamide (7o).
Yield: 73% (Off white solid); 1H-NMR (400MHz, DMSO-
d
6
): 𝛿 3.16 (t, J = 4.40Hz, 4H), 3.68 (t, J = 5.20Hz, 4H),
7.10 (dd, J = 1.84, 7.42Hz, 2H), 8.09–8.14 (m, 2H), 8.71
(d, J = 2.25Hz, 1H), 8.82 (d, J = 2.44Hz, 1H), 9.27 (s,













: C, 43.28; H, 3.23; N, 19.63; Found: C, 43.38;
H, 3.42; N, 19.60%.
2.2. Anticonvulsant Evaluation
2.2.1. Animals. Male wistar rats procured from the National
Institute of Nutrition, Hyderabad (190–220 g), were used in
the present study. The animals were kept in individual cages
for one week to acclimatize for the laboratory conditions.
They were allowed to free access of water and food.
All the experimental procedures were carried out in
accordance with Committee for the Purpose of Control
and Supervision of Experiments on Animals (CPCSEA)
guidelines.The studywas reviewed and approved by the Insti-
tutional Animal Ethics Committee, G Pulla Reddy College of
Pharmacy, Hyderabad, India.
2.2.2. Maximal Electroshock Seizure Model (MES). Maximal
electroshock seizure model was used in the present study
to evaluate the anticonvulsant activity of the compounds
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Table 1: Chemical structure and melting range of pyrazine substituted 1,3,4-thiadiazole derivatives 7(a–o).
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Table 1: Continued.



















































































































on male wistar rats. Seizures were induced in rats by
delivering electro shock of 150mA for 0.2 s by means of a
convulsiometer through a pair of ear clip electrodes. The
test compounds (100mg/kg) were administered by oral route
in the form of solution (the compounds were dissolved
in 1% sodium carboxymethyl cellulose), 30 minutes before
the maximal electroshock seizure test. The animals were
observed closely for 2 minutes. The percentage of inhibition


































































Table 2: Effect of compounds in the maximal electroshock seizure
test.

















Control (vehicle) 8.21 —
𝐸/𝐹 = Extension/Flexion [Decrease in ratio of extension phase (in sec-
onds)/flexion phase (in seconds)].
% Protection = (control−test)/(control)∗ 100.
of seizure relative to control was recorded and calculated [25].
Phenytoin (100mg/kg) was used as a standard drug.
2.2.3. Neurotoxicity Screening. Acute neurological toxicity in
mice was evaluated by rotarod test [25]. The mice were
trained to stay on the accelerating rotarod that rotates at
10 revolutions per minute. The rod diameter was 3.2 cm.
Trained animals were administered with the test compounds
Table 3: Neurotoxicity screening of the compounds 7(a–o).
Compound Neurotoxicity screen
0.5 h 1 h 2 h 4 h
7a 0/4 0/4 0/4 0/4
7b 0/4 0/4 0/4 0/4
7c 0/4 0/4 1/4 1/4
7d 0/4 0/4 0/4 0/4
7e 0/4 0/4 0/4 0/4
7f 0/4 0/4 0/4 0/4
7g 0/4 0/4 0/4 0/4
7h 0/4 0/4 1/4 1/4
7i 0/4 0/4 0/4 0/4
7j 0/4 0/4 0/4 0/4
7k 0/4 0/4 0/4 0/4
7l 0/4 0/4 1/4 1/4
7m 0/4 0/4 0/4 0/4
7n 0/4 0/4 0/4 0/4
7o 0/4 0/4 0/4 0/4
Standard 0/4 0/4 0/4 0/4
The data in the table represent the ratio between the numbers of the animals
that exhibited neurotoxicity against the number of tested animals.
at the dose of 100mg/kg. Neurotoxicity was indicated by the
inability of the animal to maintain equilibrium on the rod for
at least one minute in each of the three trails. Phenytoin was
used as a standard drug.
2.2.4. Statistical Analysis. In the present study, data were
analyzed by one way analysis of variance (ANOVA) followed
by dunnett test to compare difference between the groups.
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3. Results and Discussion
3.1. Chemistry. New pyrazine substituted 1,3,4-thiadiazole
derivatives 7(a–o) were synthesized according to Scheme 1.
Readily available starting materials and simple synthesizing
procedures make this method very attractive and convenient
for the synthesis of various thiadiazoles. Formation of prod-
ucts was confirmed by recording their elemental analyses, 1H
NMR and mass spectra. The 1H NMR, spectra of 7g showed
piperazine ring in the region of 𝛿, 3.31–3.88.Themass spectra
of 7g showed molecular ion peak at m/z 566.4 which is













The elemental analyses data showed good agreement between
the experimentally determined values and the theoretically
calculated values within ± 0.4 %.The chemical structures and
physical data of all the synthesized compounds are tabulated
in Table 1.
3.2. Biological Activity. In the present study, the anticon-
vulsant activity of the synthesized compounds 7(a–o) was
evaluated by MES model at the dose of 100mg/kg and the
results are summarized in Table 2. Compounds 7d and 7g
demonstrated significant protective effect on MES induced
seizure and the effect of 7d and 7g was similar to that
of standard (phenytoin). Similarly, compounds 7f, 7j, 7k,
7m, 7n, and 7o also showed good protective effect. Com-
pounds 7a, 7b, 7c, 7e, 7h, 7i, and 7l have relatively lower
anticonvulsant potencies. All the compounds were examined
for their neurotoxicity using rotarod method given in the
dose of 100mg/kg. Except compounds 7c, 7h, and 7l, none
of the compounds showed neurotoxicity. These compounds
showed 25% toxicity compared to standard at 2 h of oral
administration (Table 3).
The structural activity relationship study of these com-
pounds indicate that the introduction of a piperazine group
of pyrazine ring and 3,5-bis(trifluoromethyl) positions of
the benzenesulfonyl moiety showed the best anticonvulsant
activity in 7g. Compound 7d contains halogen and thiophene
group showed good anticonvulsant activity in the MES
model. Both compounds did not exhibit neurotoxicity at the
highest administered dose. Compounds with phenyl ring in
7h exhibited more anticonvulsant activity in comparison to
methyl group (7c). Compounds 7c, 7h, and 7l contribute
25% of neurotoxicity at 2 h. Among the synthesized com-
pounds 7(a–o), all the compounds showed activity in the
range of 9.43–74.88% in comparison to phenytoin which
completely inhibited the convulsions produced by electro-
convulsometer, but compound 7g having electron withdraw-
ing groups showed excellent anticonvulsant activity.
4. Conclusions
In conclusion, a series of new pyrazine substituted 1,3,4-
thiadiazole derivatives 7(a–o)were synthesized in good yield,
characterized by different spectral studies, and their anti-
convulsant activity have been evaluated. Various thiadiazole
derivatives with electron withdrawing groups showed potent
anticonvulsant activity. Among the synthesized compounds,
7d and 7g showed excellent anticonvulsant activity. Com-
pounds having thiadiazole ring showed better biological
activities than compounds having oxadiazole ring.
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